A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE Mono-1
- Sponsors Pfizer
- 12 Nov 2023 Results of post hoc pooled analysis from phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials assessing the efficacy and safety of abrocitinib in patients with atopic dermatitis and allergic comorbidities, published in the Allergy.
- 08 Nov 2023 Results of pooled post hoc NCT02780167, NCT03349060, NCT03575871 assessing efficacy and safety of abrocitinib based on patient race, ethnicity, and Fitzpatrick skin type published in the Annals of Allergy, Asthma and Immunology
- 01 Oct 2023 Results of pooled analysis from JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) and JADE EXTEND assessing patient-reported outcomes with long-term abrocitinib treatment in patients with moderate-to-severe AD published in the Journal of the European Academy of Dermatology and Venereology